Skip to contents

Tefibazumab (Cao 2013)

Source: vignettes/articles/Cao_2013_tefibazumab.Rmd
Cao_2013_tefibazumab.Rmd

Model and source

  • Citation: Cao Y, Balthasar JP, Jusko WJ. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn. 2013 Oct;40(5):597-607.
  • Article: https://doi.org/10.1007/s10928-013-9332-2
  • Source data digitised from Hetherington S et al. Antimicrob Agents Chemother. 2006;50(10):3499-3500 (PMID 17005843).

This is the tefibazumab entry from the 12-fit Cao 2013 mAb cohort. The structural model (4-compartment mPBPK: plasma + tight-tissue interstitial fluid + leaky-tissue interstitial fluid + lymph) is shared by all 12 mAbs in the paper; each mAb has its own values of sigma1, sigma2, and CLp (Model A) or CLi (Model B). This file uses Model A (clearance from plasma) per the operator’s choice for the canonical entries.

Population

Cao et al. fit the mPBPK model to tefibazumab plasma concentration profiles digitised from Hetherington 2006, humanized IgG1 anti-clumping factor A from Staphylococcus aureus in subjects with end-stage renal disease requiring hemodialysis. Doses: 10, 20 mg/kg IV. Cao 2013 does not reproduce the underlying Hetherington 2006 demographics; consult the source publication for age, sex, and other baseline characteristics. Cao 2013 used a 70 kg reference body weight when assigning the human physiological constants (V_p = 2.6 L, ISF = 15.6 L, lymph flow = 2.9 L/day).

The packaged metadata (readModelDb("Cao_2013_tefibazumab")$population) records this study context.

Source trace

Equation / parameter Value Source location
4-compartment mPBPK ODE system – Cao 2013 Eqs 1-4 (page 3, Model A)
Lumped tissue-volume splits (V_tight = 0.65 * ISF * Kp; V_leaky = 0.35 * ISF * Kp) – Cao 2013 Eq 6
Lymph-flow splits (L1 = 0.33 * L; L2 = 0.67 * L) – Cao 2013 Eq 7
sigma1 (vascular reflection coefficient, tight tissues) 0.902 Cao 2013 Table 2, tefibazumab Model A (CV 7.37%)
sigma2 (vascular reflection coefficient, leaky tissues) 0.815 Cao 2013 Table 2, tefibazumab Model A (CV 7.56%)
CLp (plasma clearance) 0.00933 L/hr = 0.22392 L/day Cao 2013 Table 2, tefibazumab Model A (CV 4.19%)
sigmaL (lymphatic capillary reflection coefficient) 0.2 (fixed) Cao 2013 Methods (assumed)
Kp (available ISF fraction for native IgG1) 0.8 Cao 2013 Methods, refs 22-23
Vplasma for 70 kg adult 2.6 L Cao 2013 Table 2 footnote
ISF total interstitial fluid for 70 kg adult 15.6 L Cao 2013 Methods (refs 24-25)
Total lymph flow for 70 kg adult 2.9 L/day Cao 2013 Methods (refs 24-25)
Vlymph (assumed equal to plasma volume) 2.6 L Cao 2013 Methods, ref 21

Virtual cohort

The packaged model has no IIV and no residual error – it is a typical-value structural mPBPK model fit by Cao 2013 to digitised mean profiles in ADAPT 5. Simulation reproduces the paper’s typical-value fits.

obs_times <- sort(unique(c(seq(0, 1, by = 0.05),
                            seq(1, 14, by = 0.5),
                            seq(14, 100, by = 2))))

make_dose_panel <- function(dose_mg_per_kg, weight_kg = 70, id) {
  amt <- dose_mg_per_kg * weight_kg
  rxode2::et(amt = amt, cmt = "plasma", id = id) |>
    rxode2::et(time = obs_times, id = id)
}

events <- dplyr::bind_rows(
  as.data.frame(make_dose_panel(10,  id = 1L)) |> dplyr::mutate(dose_mg_per_kg = 10),
  as.data.frame(make_dose_panel(20,  id = 2L)) |> dplyr::mutate(dose_mg_per_kg = 20)
)
stopifnot(!anyDuplicated(unique(events[, c("id", "time", "evid")])))

Simulation 

mod <- readModelDb("Cao_2013_tefibazumab")
sim <- rxode2::rxSolve(rxode2::rxode2(mod), events = events,
                       keep = "dose_mg_per_kg") |>
  as.data.frame()

Replicate Figure 5 (tefibazumab panel) 

sim |>
  dplyr::filter(time > 0) |>
  ggplot2::ggplot(ggplot2::aes(time, Cc,
                                colour = factor(dose_mg_per_kg))) +
  ggplot2::geom_line() +
  ggplot2::scale_y_log10() +
  ggplot2::labs(
    x = "Time (day)", y = "Plasma concentration (mg/L)",
    colour = "Dose (mg/kg)",
    title = "Cao 2013 Figure 5 (tefibazumab panel) -- typical-value reproduction",
    caption = "Replicates the tefibazumab panel of Cao 2013 Figure 5 using the packaged Model A mPBPK fit."
  )

PKNCA validation

Run NCA on the simulated plasma profile to compute Cmax, t_max, AUC_inf, and terminal half-life. The packaged model has no IIV, so a single trajectory per dose group represents the “typical” patient.

sim_nca <- sim |>
  dplyr::filter(!is.na(Cc), Cc > 0) |>
  dplyr::transmute(id = id, time = time, conc = Cc,
                   dose_mg_per_kg = dose_mg_per_kg)

dose_df <- events |>
  dplyr::filter(evid == 1) |>
  dplyr::transmute(id = id, time = time, amt = amt,
                   dose_mg_per_kg = dose_mg_per_kg)

conc_obj <- PKNCA::PKNCAconc(sim_nca, conc ~ time | dose_mg_per_kg + id)
dose_obj <- PKNCA::PKNCAdose(dose_df, amt ~ time | dose_mg_per_kg + id)

intervals <- data.frame(
  start      = 0,
  end        = Inf,
  cmax       = TRUE,
  tmax       = TRUE,
  aucinf.obs = TRUE,
  half.life  = TRUE
)

nca <- PKNCA::pk.nca(PKNCA::PKNCAdata(conc_obj, dose_obj, intervals = intervals))
nca_summary <- summary(nca)
knitr::kable(nca_summary, caption = "Simulated NCA parameters by dose group (Cao 2013 tefibazumab Model A typical-value fit).")
Simulated NCA parameters by dose group (Cao 2013 tefibazumab Model A typical-value fit).
start end dose_mg_per_kg N cmax tmax half.life aucinf.obs
0 Inf 10 1 269 0.000 18.1 3130
0 Inf 20 1 538 0.000 18.1 6250

The terminal half-life predicted by the typical-value mPBPK fit corresponds to tefibazumab’s reported half-life of approximately 2-3 weeks in the underlying Hetherington 2006 study; Cmax and AUC scale linearly with dose because the model is purely linear (no TMDD, no concentration-dependent clearance).

Assumptions and deviations

  • No IIV, no residual error. Cao 2013 fit the mPBPK model in ADAPT 5 to digitised mean profiles using a typical-value variance model V_i = (intercept + slope * Y_hat)^2 (Eq 9). Cao 2013 does not report the values of intercept and slope. The packaged model is a structural typical-value fit; downstream users wanting between-subject variability must add their own IIV.
  • Compartment names deviate from the nlmixr2lib canonical set (plasma, tight, leaky, lymph instead of central, peripheral1, peripheral2, effect). The deviation is necessary because the four mPBPK compartments are mechanistically distinct (plasma vs. tight-tissue ISF vs. leaky-tissue ISF vs. lymph) and forcing them into the canonical PK-style names would obscure the physiology. checkModelConventions() raises this as four warnings (one per compartment) and no errors.
  • Kp = 0.8 is hard-coded for native IgG1. Siltuximab is a chimeric IgG1; native-IgG1 Kp is appropriate. Cao 2013 also uses Kp = 0.4 for native IgG4 elsewhere in the cohort, but the value is not estimated and is not modified subject-to-subject.
  • 70 kg reference body weight. Cao 2013 used a fixed 70 kg adult plasma volume, ISF volume, and lymph flow (Vplasma = 2.6 L, ISF = 15.6 L, L = 2.9 L/day). For paediatric or markedly under- or over-weight subjects, the user must rescale these constants.
  • Model A (clearance from plasma) used by default. Cao 2013 also reports Model B (clearance from interstitial fluid; CLi = 0.0215 L/hr for tefibazumab); Model A is used here for consistency across the 12 nlmixr2lib entries from this paper. Cao 2013 reports a slightly lower objective-function value for Model B in 7 of 10 human mAbs but notes that Model A is more reasonable on the latent constraint sigma1 > sigma2.- Drug-specific note. Cao 2013 explicitly recommends Model A for tefibazumab on the basis of the latent constraint sigma1 > sigma2, even though Model B has a slightly lower objective function value.